Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys Launches Partnership with CellnTec for MRM-MS Assay Development

Premium

Swiss proteomics firm Biognosys has launched a partnership with cell culture company CellnTec to study the proteomics of aging.

Under the partnership, Biognosys has created a custom multiple-reaction monitoring mass spec assay for quantifying proteins linked to aging and screening for anti-aging substances.

The assay quantifies 100 proteins involved in age-related processes. Using it in combination with CellnTec's VitroAge culture medium – which is designed to encourage the natural aging of cultured cells – CellnTec has identified a number of proteins linked to the aging process and aims to develop mechanistic understandings of the anti-aging abilities of various agents.

Financial and other terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.